189 related articles for article (PubMed ID: 9721872)
61. Cycloheximide inhibits the cytotoxicity of paclitaxel (Taxol).
Liebmann J; Cook JA; Teague D; Fisher J; Mitchell JB
Anticancer Drugs; 1994 Jun; 5(3):287-92. PubMed ID: 7919452
[TBL] [Abstract][Full Text] [Related]
62. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
[TBL] [Abstract][Full Text] [Related]
63. Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells.
Marth C; Zeimet AG; Widschwendter M; Ludescher C; Kaern J; Tropé C; Gastl G; Daxenbichler G; Dapunt O
Cancer Res; 1997 Sep; 57(17):3818-22. PubMed ID: 9288793
[TBL] [Abstract][Full Text] [Related]
64. Mos oncogene expression in human ovarian tumors.
Xerri L; Charpin C; Hassoun J; Birnbaum D; Delapeyriere O
Anticancer Res; 1991; 11(4):1629-34. PubMed ID: 1836123
[TBL] [Abstract][Full Text] [Related]
65. [Reversing paclitaxel-resistance of SKOV3-TR30 cell line by curcumin].
Qiu J; Fu YF; Cheng Q; Cheng XD; Xie X; Lü WG
Zhonghua Yi Xue Za Zhi; 2012 Jul; 92(27):1926-8. PubMed ID: 23134969
[TBL] [Abstract][Full Text] [Related]
66. PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.
Aaltonen V; Koivunen J; Laato M; Peltonen J
Cancer Lett; 2007 Aug; 253(1):97-107. PubMed ID: 17320279
[TBL] [Abstract][Full Text] [Related]
67. Biological characteristics of Taxol‑resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53.
Liu Q; Sui R; Li R; Miao J; Liu J
Mol Med Rep; 2015 Feb; 11(2):1292-7. PubMed ID: 25351378
[TBL] [Abstract][Full Text] [Related]
68. p34cdc2 protein is complexed with the c-mos protein in rat skeletal muscle.
Leibovitch SA; Guillier M; Lenormand JL; Leibovitch MP
Oncogene; 1993 Sep; 8(9):2361-9. PubMed ID: 8395677
[TBL] [Abstract][Full Text] [Related]
69. Overexpression of glycogen synthase kinase-3 in ovarian carcinoma cells with acquired paclitaxel resistance.
Fu Y; Hu D; Qiu J; Xie X; Ye F; Lu WG
Int J Gynecol Cancer; 2011 Apr; 21(3):439-44. PubMed ID: 21436692
[TBL] [Abstract][Full Text] [Related]
70. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel.
Nishio K; Arioka H; Ishida T; Fukumoto H; Kurokawa H; Sata M; Ohata M; Saijo N
Int J Cancer; 1995 Nov; 63(5):688-93. PubMed ID: 7591286
[TBL] [Abstract][Full Text] [Related]
71. Cyclin-dependent kinase 1 inhibitor RO3306 promotes mitotic slippage in paclitaxel-treated HepG2 cells.
Xiao J; Qiu P; Lai X; He P; Wu Y; Du B; Tan Y
Neoplasma; 2014; 61(1):41-7. PubMed ID: 24195507
[TBL] [Abstract][Full Text] [Related]
72. Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.
Pennati M; Campbell AJ; Curto M; Binda M; Cheng Y; Wang LZ; Curtin N; Golding BT; Griffin RJ; Hardcastle IR; Henderson A; Zaffaroni N; Newell DR
Mol Cancer Ther; 2005 Sep; 4(9):1328-37. PubMed ID: 16170024
[TBL] [Abstract][Full Text] [Related]
73. Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line.
Panvichian R; Orth K; Pilat MJ; Day ML; Day KC; Yee C; Kamradt JM; Pienta KJ
Urology; 1999 Oct; 54(4):746-52. PubMed ID: 10510942
[TBL] [Abstract][Full Text] [Related]
74. Mos mediates the mitotic activation of p42 MAPK in Xenopus egg extracts.
Yue J; Ferrell JE
Curr Biol; 2004 Sep; 14(17):1581-6. PubMed ID: 15341746
[TBL] [Abstract][Full Text] [Related]
75. The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis.
Huang Y; Fang Y; Dziadyk JM; Norris JS; Fan W
Oncol Res; 2002; 13(2):113-22. PubMed ID: 12392159
[TBL] [Abstract][Full Text] [Related]
76. Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel.
Moongkarndi P; Kaslungka S; Kosem N; Junnu S; Jongsomboonkusol S; Theptaranon Y; Neungton N
Asian Pac J Allergy Immunol; 2003 Mar; 21(1):31-41. PubMed ID: 12931749
[TBL] [Abstract][Full Text] [Related]
77. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.
Wang T; Lv JH; Zhang XF; Li CJ; Han X; Sun YJ
Int J Cancer; 2010 Jan; 126(2):362-70. PubMed ID: 19609944
[TBL] [Abstract][Full Text] [Related]
78. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.
Ling X; Bernacki RJ; Brattain MG; Li F
J Biol Chem; 2004 Apr; 279(15):15196-203. PubMed ID: 14722122
[TBL] [Abstract][Full Text] [Related]
79. [Induction effect of rapamycin combined paclitaxel on apoptosis of ovarian cancer cell lines A2780 and SKOV3 and the molecular mechanism].
Ma XY; Wang SX; Liu Y; Liu RH; Lu YP; Ma D
Ai Zheng; 2007 Apr; 26(4):367-70. PubMed ID: 17430653
[TBL] [Abstract][Full Text] [Related]
80. Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation.
Rakovitch E; Mellado W; Hall EJ; Pandita TK; Sawant S; Geard CR
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1119-24. PubMed ID: 10421546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
